Ibex Medical Analytics Launches Next-Generation AI Pathology Platform
Published: 09 Apr 2026
Author: Towards Healthcare
Ibex Medical Analytics has unveiled Ibex 4, its next-generation AI-powered pathology, designed to support pathologists facing rising case volumes and increasing diagnostic complexity. It is a global leader in clinical-grade AI-powered pathology.
Challenges faced by the pathology department include rising case volumes and increasing diagnostic complexity. Ibex 4 provides a future-ready solution that alleviates these pressures.
According to Towards Healthcare, the breast biopsy devices market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 7.03 billion in 2026 to approximately USD 13.82 billion by 2035, representing a compound annual growth rate (CAGR) of 7.8% from 2026 to 2035. Growth is driven by the increasing incidence of breast cancer, along with technological innovation, and support of government initiatives to focus on the biopsy devices market to enhance diagnostic accuracy and efficiency.
Expanded Breast Diagnostic Capabilities
The advancements in breast diagnostic capabilities are driven by innovative technologies and methodologies that enhance the accuracy and efficiency of breast cancer detection. Ibex Medical Analytics, Ibex 4 is an AI-powered pathology platform support pathologist with an advanced workflow for cancer diagnostics with IHC quantification and visualisation tools.
The update of the latest Breast Imaging Reporting and Data System Atlas incorporates new descriptors, modalities, and auditing methods to modernise breast imaging reporting standards. This reflects the need for complex breast imaging practise.
Regulatory Status and Industry Presence
This market is governed by various regulations that ensure safety, efficiency, and quality of devices used in breast cancer diagnosis and treatment. The market is supported by the government initiative promoting breast cancer awareness and screening program which encourage early detection and diagnosis.
The preference for shifting market growth toward smarter guidance and better targeting and refinement of the vacuum-assisted and core biopsy platform to improve ergonomics, speed, and sample handling. Due to a strong regulatory presence and robust industry presence, companies will be pushed to expand in the coming years.
A recent report by Towards Healthcare highlights that the Breast biopsy devices market is witnessing growth due to the rising prevalence of breast cancer, with increasing adoption of minimally invasive diagnostic procedures and continuous technological advancement in biopsy systems.